Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD, USA.
Department of Rheumatology, Policlinico S. Matteo, IRCCS Fondazione, Pavia, Italy; University of Pavia, PhD in Experimental Medicine, Pavia, Italy.
Semin Arthritis Rheum. 2022 Aug;55:152021. doi: 10.1016/j.semarthrit.2022.152021. Epub 2022 Apr 28.
ANCA-associated vasculitis (AAV) is characterized by fluctuating levels of disease activity, but no formal criteria exist to measure response to treatment. This Delphi exercise aimed to reach consensus about which measures are considered by patients and physicians to be most important when assessing response to treatment in clinical trials of AAV.
An international 3-round online Delphi exercise was conducted. Survey participants included patients with AAV and physicians with expertise in AAV. Survey participants were asked to rate (on a scale of 1-9) the importance of each item when assessing response to treatment in AAV. Items scored 7-9 by ≥70% participants were considered highly important.
89 patients and 176 physicians completed three rounds of the Delphi exercise. The most highly rated items of response involved disease activity [extent of organ involvement, physician global assessment], mortality [survival], and patient-reported outcomes [patient global assessment and health-related quality of life measures]. Achievement of specific BVAS scores were highly rated only by physicians. Items highly rated only by patients included laboratory measures [changes on urinalysis and acute phase reactants], pain, and fatigue. Additional items related to damage and adverse events were highly rated by both groups.
There is consensus between patients and physicians on many items considered important to measure when assessing response to treatment in AAV. There are some items considered important by only patients or only physicians. These data will inform the next steps in the development criteria of response to treatment in AAV.
抗中性粒细胞胞浆抗体相关性血管炎(AAV)的特征是疾病活动水平波动,但目前尚无正式标准来衡量治疗反应。本德尔菲研究旨在就评估 AAV 临床试验中治疗反应时,患者和医生认为哪些措施最重要达成共识。
进行了一项国际性的 3 轮在线德尔菲研究。调查参与者包括 AAV 患者和具有 AAV 专业知识的医生。调查参与者被要求对评估 AAV 治疗反应时的每个项目的重要性进行评分(1-9 分)。得分≥70%的项目被认为非常重要。
89 名患者和 176 名医生完成了 3 轮德尔菲研究。最受重视的反应项目涉及疾病活动度[器官受累程度、医生整体评估]、死亡率[生存]和患者报告的结局[患者整体评估和健康相关生活质量措施]。只有医生高度重视达到特定 BVAS 评分。只有患者高度重视的项目包括实验室指标[尿液分析和急性期反应物的变化]、疼痛和疲劳。两组均高度重视与损害和不良事件相关的其他项目。
患者和医生在评估 AAV 治疗反应时,对许多被认为重要的项目有共识。有些项目仅被患者或医生认为重要。这些数据将为 AAV 治疗反应评估标准的下一步发展提供信息。